Taken together, our data establish that endogenous levels of oncogenic KRAS expression render cells more resistant to ferroptosis by upregulating FSP1 through the NRF2 and MAPK pathway allowing for a superior capacity to buffer acute lipid peroxidation during tumor initiation. Here, KRAS is linked to neoplasm.